News
-
-
-
-
REGULATED PRESS RELEASE
Disclosure of transactions in own shares from December 16 to December 20, 2024
-
PRESS RELEASE
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation -
-
PRESS RELEASE
Syngenta Group (HK) Holdings Company Limited concludes USD 4,500 million syndicated sustainability-linked term loan facility
Syngenta Group (HK) Holdings Company concludes USD 4,500 million syndicated sustainability-linked term loan facility with banks worldwide. Loan linked to sustainability targets, reflecting company's commitment to innovation and value creation -
-
-
PRESS RELEASE
EQS-Adhoc: SNP: Conclusion of an Investment Agreement with Carlyle and Announcement of a Voluntary Public Takeover Offer and Subsequent Delisting
SNP Schneider-Neureither & Partner SE concludes an investment agreement with Carlyle, announcing a voluntary public takeover offer and subsequent delisting for strategic growth